ClinicalTrials.gg
RecruitingNCT07322003PREVAiLSUpdated Oct 27, 2026

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

A Phase 3 interventional study of Pridopidine and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Prilenia. Recruiting at 56 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Prilenia · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 27, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
13th of 307
500 · median 33
Started
2026
with 32 others
Phase 3
30 of 440
3 open now
Primary completion
2028-03
later than 76 of 128 live
Registered
415th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 13th largest by planned enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2026, is one of 30 in phase 3, reaches primary completion later than 76 of the 128 other live ones, and was the 415th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

92 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is:

Does pridopidine slow disease progression of ALS?

Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS.

Participants will:

Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks.

Visit the clinic once every 1-3 months for checkups and tests

Read the detailed description

This is a Phase 3, randomized study consisting of a double-blind placebo-controlled (DBPC) period followed by an open-label extension (OLE) to evaluate the efficacy and safety of pridopidine administered orally at a dose of 45 mg twice a day in adult participants with early and rapidly progressing ALS. Standard of care treatments (e.g. riluzole, edaravone and Nuedexta) will be allowed as long as participants are on a stable dose for at least 4 weeks prior to dosing. In the DBPC period, participants will be randomized in a 3:2 ratio to the pridopidine and placebo arms.

In the DBPC period, participants will receive pridopidine or placebo for 48 weeks. In the OLE period, all participants will receive pridopidine for 48 weeks, while maintaining the blind to their original randomization for both the participant as well as the Investigator and other clinical staff. The total study duration per participant will be 102 weeks including screening and follow up.

Throughout the study, participants will be assessed through on-site clinic visits and virtual visits (via telephone).

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Definite ALS or Probable ALS using the El Escorial criteria.
  • Symptom onset of ≤18 months at screening.
  • Slow vital capacity (SVC) greater or equal to 60% predicted.
  • Treatment Research Initiative to Cure ALS (TRICALS) Risk Profile Calculator score, based on the European Network for the Cure of ALS (ENCALS) survival prediction model, in the range of -6 to -2, inclusive, at screening.
  • Able to swallow a capsule.

Key Exclusion Criteria:

  • Presence of tracheostomy or permanent assisted ventilation.
  • heart disease, clinically significant history of arrhythmia, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia, or presence of left bundle branch block.
  • Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide and participate in the study.
  • Clinically significant and/or unstable medical condition (other than ALS) that may either pose a clinically meaningful risk to the participant and/or to study completion.
  • Use of medications that prolong .
  • Previous treatment with pridopidine, gene therapy, or antisense oligonucleotides.
  • Confirmed mutation in the SOD1, FUS or C9orf72 gene.
  • Pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Pridopidine

    Pridopidine hard gelatin capsules of 45 mg strength. During titration period 1 capsule taken orally in the morning for 2 weeks. During the main treatment period, 1 capsule in the morning and 1 capsule in the afternoon taken orally. Total daily dose of 90 mg.

    Drug: Pridopidine

  • Placebo comparator
    Placebo

    Placebo hard gelatin capsules. During titration period 1 capsule taken orally in the morning for 2 weeks. During the main treatment period, 1 capsule in the morning and 1 capsule in the afternoon taken orally.

    Drug: Placebo

Interventions

  • Pridopidine hard gelatin capsule.

  • DrugPlacebo

    Placebo hard gelatin capsule.

06

What researchers measure

Primary outcomes

  1. Change from baseline through Week 26 and Week 48 in the Revised ALS Functional Rating Scale (ALSFRS-R) total score adjusted for mortality

    The ALSFRS-R encompasses 12 questions grouped into 4 domains to assess bulbar symptoms, limb and trunk functionality, respiratory symptoms, and the need for percutaneous endoscopic gastrostomy (PEG), non-invasive ventilation, or tracheostomy with invasive ventilation. Each function is scored from 0 (no ability) to 4 (normal), with a minimum total score of 0 and maximum total score of 48. Higher scores indicate better functioning.

    Time frame: Baseline to Week 48

Secondary outcomes

  1. Overall survival at Week 96

    Time to death in days from baseline as assessed at the end of open-label extension (OLE) period

    Time frame: Baseline to Week 96

  2. Change from baseline through Week 26 and Week 48 in speaking rate as measured by quantitative speech assessment in the clinic

    Time frame: Baseline to Week 48

  3. Change from baseline through Week 48 in intelligibility of speech by quantitative speech assessment in the clinic.

    Time frame: Baseline to Week 48.

  4. Change from baseline through Week 48 in percent predicted slow vital capacity (SVC)

    SVC measures the maximal amount of air exhaled in a relaxed expiration from full inspiration to residual volume. SVC is assessed in the sitting position with a spirometer.

    Time frame: Baseline to Week 48

  5. Change from baseline through Week 48 in the Bulbar subdomain of the ALSFRS-R

    Measures decline in bulbar function.

    Time frame: Baseline to Week 48

  6. Change from baseline through Week 48 in the Amyotrophic Lateral Sclerosis Assessment Questionnaire - 40 (ALSAQ-40)

    ALSAQ-40 includes 40 items/questions with 5 discrete scales including physical mobility (10 items), activities of daily living and independence (10 items), eating and drinking (3 items), communication (7 items), and emotional reactions (10 items). The questions refer to two weeks prior to the day of the application and the answers are given according to the following variables: never, rarely, sometimes, frequently and always. The score ranges from 0 to 100; the higher the score, the worse the quality of life.

    Time frame: Baseline to Week 48

07

Study locations

56 of 56 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 7, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. McMaster University Medical Centre is now Recruiting
Show 2 added (2 Germany)
  • Medical School Hannover, ALS Centre · Hanover, Germany
  • Universitaetsklinikum Schleswig-Holstein, Campus Luebeck · Lübeck, Germany
Show 1 removed
  • Universitätsklinikum Schleswig-Holstein · München, Germany
across 2 updates, Oct 6, 2026 – Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    2 sites added, 1 site removed
    Show 2 added (2 Germany)
    • Medical School Hannover, ALS Centre · Hanover, Germany
    • Universitaetsklinikum Schleswig-Holstein, Campus Luebeck · Lübeck, Germany
    Show 1 removed
    • Universitätsklinikum Schleswig-Holstein · München, Germany
  2. Oct 6, 2026
    McMaster University Medical Centre is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07322003
Lead sponsor
Prilenia
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Feb 1, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Prilenia Medical Information
Contact
MedInfo@prilenia.com
857-574-5755

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion